A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary

Gynecologic Oncology

Volumn 61, Issue 3, 1996, Pages 349-353

  Reed, Eddie ^a   Sarosy, Gisele ^a   Kohn, Elise ^a   Christian, Michaele ^a   Charles J Jr , Link ^a   Goldspiel, Barry ^a   Davis, Patricia ^a   Jacob, Joan ^a   Maher, Martha ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0029941561     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0155     Document Type: Article

References (31)

1. Rowinsky, E. K., Cazenave, L. A., and Donehower, R. C. Taxol: A novel investigational antimicrotubule agent, J. Natl. Cancer Inst. 82, 1247-1259 (1990).
2. Chabner, B. A. Taxol, P.P.O. Updates 5(9), 1-10 (1991).
3. Stierle, A., Strobel, G., and Stierle, D. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew, Science 260, 214-216 (1993).
4. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, E. K., and Donehower, R. D. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann. Intern. Med. 111(4), 273-279 (1989).
5. Sarosy, G., Kohn, E., Stone, D. A., Rothenberg, M., Jacob, J., Adamo, D. O., Ognibene, F. P., Cunnion, R. E., and Reed, E. Phase I study of taxol and G-CSF in patients with refractory ovarian cancer, J. Clin. Oncol. 10(7), 1165-1170 (1992).
6. Thigpen, T., Blessing, J., Ball, H., Hummel, S., and Barret, R. Phase II trial of taxol as second-line therapy for ovarian carcinoma, Proc. Am. Soc. Clin. Oncol. 9, 156 (1990). [Abstract 604]
7. Holmes, F. A., Walters, R. S., Theriault, R. L., Forman, A. D., Knwton, L. K., Raber, M. N., et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer, J. Natl. Cancer Inst. 83, 1791-1805 (1991).
8. Chang, A., Kim, K., Glick, J., Anderson, T., Karp, D., and Johnson, D. Phase II study of Taxol in patients with stage IV non-small cell lung cancer (NSCLS): The Eastern Cooperative Oncology Group (ECOG) results, Proc. Am. Soc. Clin. Oncol. 11, 293 (1992).
9. Legha, S. S., Ring, S., Papadopoulos, N., Raber, M., and Benjamin, R. S. A phase II trial of taxol in metastatic melanoma, Cancer 65, 2478-2481 (1990).
10. Einzig, A. I., Gorowski, E., Sasloff, J., and Wiernik, P. H. Phase II trial of taxol in patients with metastatic renal cell carcinoma, Cancer Invest. 9, 133-136 (1991).
11. Rowinsky, E. K., Burke, P. H., Karp, J. E., Tucker, R. W., Ettinger, D. S., and Donehower, R. C. Phase I and pharmacologic study of Taxol in refractory acute leukemias, Cancer Res. 49, 4640-4647 (1989).
12. Young, R. C., Perez, C. A., and Hoskins, W. J. Cancer of the ovary, in Principles and practice of oncology (V. T. Devita, Jr., S. Hellman, and S. A. Rosenberg, Eds.), Lippincott, Philadelphia, pp. 349-395 (1993).
13. Berger, N. Alkylating agents, in Principles and practice of oncology (V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg, Eds.), Lippincott, Philadelphia, pp. 400-409 (1993).
14. Chabner, B. A., and Myers, C. E. Clinical pharmacology of cancer chemotherapy, in Cancer principles and practice of oncology (V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg, Eds.), Lippincott, Philadelphia, pp. 349-395 (1989).
15. McGuire, W. P., Hoskins, W. J., Brady, M. F., et al. A phase II trial comparing cisplatin cytoxan (PC) and cisplatin/Taxol (PT) in advanced ovarian cancer (AOC), Proc. Am. Soc. Clin. Oncol. 12, 255 (1993).
16. Sarosy, G., and Reed, E. Taxol dose intensification and its clinical implications, J. Natl. Med. Assoc. 85, 427-431 (1993).
17. Link, C., Bicher, A., Kohn, E., Adamo, D. O., Davis, P., Christian, M., Reed, E., and Sarosy, G. Flexible G-CSF dosing in ovarian cancer patients receiving dose intense Taxol therapy, Blood 83, 1188-1192 (1994).
18. Bicher, A., Kohn, E., Sarosy, G., Adamo, D. O., Davis, P., Jacob, J., Christian, M., and Reed, E. The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose intense Taxol and G-CSF, Anti-Cancer Drugs 4, 141-148 (1993).
19. Parker, R. J., Dabholkar, M., Lee, K. B., Bostick-Bruton, F., and Reed, E. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells, Monogr. Natl. Cancer Inst. Suppl. 15, 83-88 (1993).
20. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grachow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B., and Donehower, R. C. Sequences of Taxol and cisplatin: A phase I and pharmacologic study, J. Clin. Oncol. 9, 1692-1703 (1991).
21. Parker, R. J., Dabholkar, M., Lee, K. B., Bostick-Bruton, F., and Reed, E. Paclitaxel reduces the repair of cisplatin-DNA damage in human ovarian cancer cells, without an effect of mRNA levels of ERCC1, Clin. Cancer Res., in press (1996).
22. Tishler, R. B., Geard, C. R., Hall, E. J., and Schliff, P. B. Taxol sensitizes human astrocytoma cells to radiation, Cancer Res. 52, 3495-3497 (1992).
23. Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., and Donehower, R. C. Cardiac disturbances during the administration of Taxol, J. Clin. Oncol. 9, 1704-1712 (1991).
24. Kohn, E. C., Sarosy, G., Bicher, A., Link, C., Christian, M., Steinberg, S., Rothenberg, M., Adamo, D. O., Davis, P., Ognibene, F., Cunnion, R., and Reed, E. Taxol: High dose intensity increases the objective response rate in platinum-resistant ovarian cancer patients, J. Natl. Cancer Inst. 86, 18-24 (1994).
25. Swenerton, K., Eisenhauer, E., ten Bokkel, W., et al. Taxol in relapsed ovarian cancer: High vs low dose and short vs long infusion, Proc. Am. Soc. Clin. Oncol. 12, 256 (1993).
26. Cleaver, J. E. It was a very good year for DNA repair, Cell 76, 1-4 (1994).
27. Lee, K. B., Parker, R. J., Bohr, V., Cornelison, T., and Reed, E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3, Carcinogenesis 14, 2177-2180 (1993).
28. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., and Reed, E. mRNA levels of XPAC and ERCC1 in ovarian cancer tissue correlates with response to platinum-based chemotherapy, J. Clin. Invest. 94, 703-708 (1994).
29. Sancar, A. Mechanisms of DNA excision repair, Science 266, 1954-1956 (1995).
30. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines, J. Clin. Oncol. 12, 2471-2508 (1994).
31. Reed, E. The use of colony stimulating factors as bone marrow support for systemic anticancer chemotherapy, J. Natl. Med. Assoc. 86, 459-464 (1994).